RxDoctor Payments Data

Amit Arbune, MD

Cardiovascular Disease · Dallas, TXNPI 1487902961

Payments from drug & device makers

$505in general payments, 2019–2025

Across 20 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$110
  • Kiniksa Pharmaceuticals, Ltd.$103
  • AstraZeneca$63
  • Johnson & Johnson$36
  • E.r. Squibb & Sons, L.L.C.$30
  • Boehringer Ingelheim$28
  • plus $135 from 8 others

What the payments were for

  • Food & beverage$505100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$505 in reported general payments places this provider in the 15th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$43,062
Medicare patients
344
Services billed
559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$67,622
JardianceEmpagliflozin35$36,534
EntrestoSacubitril/Valsartan38$35,630
FarxigaDapagliflozin Propanediol40$30,173
XareltoRivaroxaban12$15,333
Repatha SureclickEvolocumab23$13,230
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,116
Metoprolol Succinate167$1,555
Valsartan66$1,190
Bumetanide24$1,173
Atorvastatin Calcium116$696
Carvedilol114$684
Spironolactone128$607
Losartan Potassium90$496
Amlodipine Besylate55$362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$11$67,62275 claims
Boehringer IngelheimJardiance$28$36,53435 claims
NovartisEntresto$21$35,63038 claims
AstraZenecaFarxiga$63$30,17340 claims
Johnson & JohnsonXarelto$36$15,33312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →